Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Kidney Cancer

June 13, 2017

Join Eric Jonasch, MD and Marcia Holloway, APRN NP-C from The University of Texas MD Anderson Cancer Center as they present their expertise on a range of cases pertaining to kidney cancer.

Renal cell carcinoma (RCC) continues to have a significant health impact. In the United States, RCC is the sixth (6th) and eighth (8th) most common malignancy among men and women respectively, with 61,560 new cases and 14,080 deaths estimated in 2015.

Surgical resection remains the only effective therapy for clinically localized RCC. During the last three decades there have been steady improvements in surgical techniques and preoperative care, which have dramatically improved the ability to safely surgically resect tumors. Studies have demonstrated that oncologic outcomes are similar for patients undergoing partial or radical nephrectomy, particularly for patients with tumors confined to the kidney.

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, case managers, and other health care professionals who manage patients with cancer.

Additional information
Supporters: 

This educational activity is supported by educational grants from Astellas and Medivation, Inc, a Pfizer company; AstraZeneca; Bayer Healthcare Pharmaceuticals Inc.; Celgene Corporation; Eisai; Genomic Health, Inc.; Janssen Biotech, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Sanofi-Genzyme; and Takeda Oncology. This activity is supported by educational funding provided by Amgen. This activity is supported by an independent medical education grant from Bristol-Myers Squibb. This educational activity is supported by an unrestricted education grant from Exelixis, Inc. This educational activity is supported by an independent educational grant from Merck.

Course summary
Available credit: 
  • 1.00 CCM clock hours
  • 1.00 ACPE contact hours
  • 1.00 ANCC contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Course opens: 
06/13/2017
Course expires: 
08/11/2017
Event starts: 
06/13/2017 - 11:00am
Event ends: 
06/13/2017 - 12:00pm
Cost:
$0.00

Eric Jonasch, MD
The University of Texas MD Anderson Cancer Center

Marcia Holloway, APRN, NP-C
The University of Texas MD Anderson Cancer Center

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

Physicians
National Comprehensive Cancer Network is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

National Comprehensive Cancer Network designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.0 hour of Category I credit for completing this activity.

Nurses
National Comprehensive Cancer Network is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 1.0 contact hour.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. Credit approval for case managers is pending for this program.

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: TBD

Available Credit

  • 1.00 CCM clock hours
  • 1.00 ACPE contact hours
  • 1.00 ANCC contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Learning Objectives

Following this activity, participants should be able to:

  • Determine optimal surgical approaches for patient with early-stage renal cell carcinoma.
  • Choose the optimal systemic therapy for advanced renal cell carcinoma using evidence-based data and patient characteristics.
  • Apply best practices to manage the adverse events associated with the new therapies available for advanced renal cell carcinoma.

Accreditation Period

Course opens: 
06/13/2017
Course expires: 
08/11/2017

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing